Currently, there are 232.45M common shares owned by the public and among those 226.73M shares have been available to trade.
The company’s stock has a 5-day price change of -11.03% and 10.25% over the past three months. ARDX shares are trading -1.13% year to date (YTD), with the 12-month market performance up to 51.73% higher. It has a 12-month low price of $3.16 and touched a high of $10.13 over the same period. ARDX has an average intraday trading volume of 3.51 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.19%, 1.58%, and -13.69% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Ardelyx Inc (NASDAQ: ARDX) shares accounts for 62.18% of the company’s 232.45M shares outstanding.
It has a market capitalization of $1.44B and a beta (3y monthly) value of 0.89. The earnings-per-share (ttm) stands at -$0.28. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.84% over the week and 5.43% over the month.
Earnings per share for the fiscal year are expected to increase by 14.24%, and 71.28% over the next financial year. EPS should grow at an annualized rate of 30.00% over the next five years, compared to 28.61% over the past 5-year period.
Looking at the support for the ARDX, a number of firms have released research notes about the stock. Piper Sandler stated their Neutral rating for the stock in a research note on July 02, 2024, with the firm’s price target at $15-$7. Leerink Partners coverage for the Ardelyx Inc (ARDX) stock in a research note released on April 05, 2024 offered a Outperform rating with a price target of $14. Raymond James was of a view on December 18, 2023 that the stock is Strong Buy, while H.C. Wainwright gave the stock Buy rating on September 07, 2023, issuing a price target of $9. Cantor Fitzgerald on their part issued Overweight rating on August 25, 2023.
